Foursixthree Capital LP Has $8.99 Million Stake in Arbutus Biopharma Corporation $ABUS

Foursixthree Capital LP decreased its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) by 22.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,978,975 shares of the biopharmaceutical company’s stock after selling 578,392 shares during the period. Arbutus Biopharma makes up about 2.5% of Foursixthree Capital LP’s portfolio, making the stock its 9th largest position. Foursixthree Capital LP owned approximately 1.03% of Arbutus Biopharma worth $8,985,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Western Standard LLC bought a new stake in shares of Arbutus Biopharma during the third quarter worth about $2,306,000. Two Seas Capital LP lifted its position in Arbutus Biopharma by 10.3% in the 2nd quarter. Two Seas Capital LP now owns 10,443,317 shares of the biopharmaceutical company’s stock valued at $32,270,000 after acquiring an additional 977,361 shares in the last quarter. BlackBarn Capital Partners LP lifted its position in Arbutus Biopharma by 11.2% in the 2nd quarter. BlackBarn Capital Partners LP now owns 2,603,521 shares of the biopharmaceutical company’s stock valued at $8,045,000 after acquiring an additional 261,650 shares in the last quarter. Schroder Investment Management Group acquired a new position in Arbutus Biopharma during the 2nd quarter valued at about $375,000. Finally, Los Angeles Capital Management LLC bought a new stake in Arbutus Biopharma during the 2nd quarter worth approximately $61,000. 43.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Arbutus Biopharma in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.00.

Arbutus Biopharma Price Performance

ABUS opened at $4.26 on Monday. Arbutus Biopharma Corporation has a fifty-two week low of $2.70 and a fifty-two week high of $5.10. The firm has a market capitalization of $819.28 million, a P/E ratio of -18.52 and a beta of 0.69. The company’s 50-day moving average is $4.35 and its 200 day moving average is $4.41.

About Arbutus Biopharma

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.